Claire Mazumdar, Bicara Therapeutics CEO
March 6, 2023 09:16 AM ESTUpdated 09:41 AM
Financing

Red Tree, RA Cap­i­tal lead $108M in­fu­sion in­to Bicara and its bi­func­tion­al I/O drug

Amber Tong

Bicara Ther­a­peu­tics, the Bio­con spin­out work­ing on a new kind of im­munother­a­py, has bagged $108 mil­lion to push its lead can­di­date deep­er in­to the clin­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times